Adverum Biotechnologies, Inc. 00773U207 06/17/2025 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 541666 0 FOR 541666 FOR Alector, Inc. 014442107 06/11/2025 Advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 995841 0 FOR 995841 FOR AnaptysBio, Inc. 032724106 06/17/2025 To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials. SECTION 14A SAY-ON-PAY VOTES 357733 0 FOR 357733 FOR AnaptysBio, Inc. 032724106 06/17/2025 Non-binding advisory vote on the frequency of holding future advisory votes regarding named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 357733 0 1 YEAR 357733 FOR Biohaven Ltd. G1110E107 05/05/2025 A non-binding advisory vote on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 478972 0 FOR 478972 FOR Celldex Therapeutics, Inc. 15117B202 06/05/2025 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 497270 0 FOR 497270 FOR Cidara Therapeutics, Inc. 171757206 07/18/2024 Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 56725 0 FOR 56725 FOR Cidara Therapeutics, Inc. 171757206 06/18/2025 Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 56725 0 FOR 56725 FOR Dianthus Therapeutics, Inc. 252828108 05/22/2025 To approve, on an advisory basis, the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 1027711 0 FOR 1027711 FOR EyePoint Pharmaceuticals, Inc. 30233G209 06/18/2025 To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES 1050000 0 FOR 1050000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 06/18/2025 To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 1050000 0 1 YEAR 1050000 FOR Mersana Therapeutics, Inc. 59045L106 06/12/2025 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 1305000 0 FOR 1305000 FOR MoonLake Immunotherapeutics 61559X104 06/05/2025 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 282313 0 FOR 282313 FOR Praxis Precision Medicines, Inc. 74006W207 06/26/2025 To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. SECTION 14A SAY-ON-PAY VOTES 170000 0 FOR 170000 FOR Protara Therapeutics, Inc. 74365U107 06/11/2025 Approval, on an advisory basis, of the compensation of Protara Therapeutics, Inc.'s named executive officers, as disclosed in the proxy statement SECTION 14A SAY-ON-PAY VOTES 800000 0 FOR 800000 FOR scPharmaceuticals Inc. 810648105 06/03/2025 To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 1200647 0 FOR 1200647 FOR Silence Therapeutics plc 82686Q101 06/26/2025 To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the attached proxy SECTION 14A SAY-ON-PAY VOTES 476200 0 FOR 476200 FOR Silence Therapeutics plc 82686Q101 06/26/2025 To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers SECTION 14A SAY-ON-PAY VOTES 476200 0 1 YEAR 476200 FOR Skye Bioscience, Inc. 83086J200 06/06/2025 Consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission. SECTION 14A SAY-ON-PAY VOTES 8167206 0 FOR 8167206 FOR Skye Bioscience, Inc. 83086J200 06/06/2025 Consider and vote upon, on an advisory basis, whether the stockholder vote to approve the compensation of the named executive officers as required by Section 14A(a)(2) of the Securities Exchange Act of 1934, as amended, should occur every one, two or three years. SECTION 14A SAY-ON-PAY VOTES 8167206 0 1 YEAR 8167206 FOR Tectonic Therapeutic, Inc. 878972108 06/06/2025 Advisory approval of the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 511660 0 FOR 511660 FOR Tectonic Therapeutic, Inc. 878972108 06/06/2025 Advisory vote on the frequency of stockholder advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES 511660 0 1 YEAR 511660 FOR Viking Therapeutics, Inc. 92686J106 05/20/2025 To Approve, On An Advisory Basis, The Compensation Of Our Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 189593 0 FOR 189593 FOR Viridian Therapeutics, Inc. 92790C104 06/20/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 736595 0 FOR 736595 FOR Zentalis Pharmaceuticals, Inc. 98943L107 06/17/2025 To approve, on an advisory (non-binding) basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 490000 0 FOR 490000 FOR